Overview of α-Blocker Therapy for Benign Prostatic Hyperplasia
- 1 April 1998
- Vol. 51 (4) , 38-45
- https://doi.org/10.1016/s0090-4295(98)00054-5
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Doxazosin for Benign Prostatic Hyperplasia: Long-term Efficacy and Safety in Hypertensive and Normotensive PatientsJournal of Urology, 1997
- Tamsulosin, a selective α1c‐adrenoceptor* antagonist: a randomized, controlled trial in patients with benign prostatic ‘obstruction’ (symptomatic BPH)British Journal of Urology, 1995
- Alpha1-adrenoceptors in human prostate: Characterization and binding characteristics of alpha1-antagonistsLife Sciences, 1994
- Long‐term treatment of benign prostatic hyperplasia with alfuzosin: a 24–30 month surveyBritish Journal of Urology, 1994
- Alpha‐blocking Treatment with Alfuzosin in Symptomatic Benign Prostatic Hyperplasia: Comparative Study with PrazosinBritish Journal of Urology, 1993
- Comparative Study of Selective α1‐Adrenoceptor Blockade versus Surgery in the Treatment of Prostatic ObstructionPublished by Wiley ,1993
- New Therapies for Benign Prostatic HyperplasiaMayo Clinic Proceedings, 1992
- The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscleThe Prostate, 1992
- Prazosin in the Treatment of Prostatic Obstruction A Placebo‐controlled StudyBritish Journal of Urology, 1987
- A Double‐blind Controlled Trial of a New α‐1 Blocking Drug in the Treatment of Bladder Outflow ObstructionBritish Journal of Urology, 1985